• Explore /
  • Poster
  • / Real-world outcomes in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) receiving second-line (2L) chemotherapy (CT) vs alternative androgen receptor-targeted agents (ARTA) after lack of response to first-line (1L) ARTA in US community oncology practices.

Real-world outcomes in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) receiving second-line (2L) chemotherapy (CT) vs alternative androgen receptor-targeted agents (ARTA) after lack of response to first-line (1L) ARTA in US community oncology practices.

Abstract Poster

Authors

William Oh

William K. Oh

Division of Hematology and Medical Oncology, The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY

William K. Oh , Wendy Y. Cheng , Raymond Miao , Francis Vekeman , Marjolaine Gauthier-Loiselle , Mei Sheng Duh , Edward Drea , Ted P. Szatrowski

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2017 Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session A: Prostate Cancer

Track

Prostate Cancer,Prostate Cancer

Sub Track

Prostate Cancer - Advanced Disease

Citation

J Clin Oncol 35, 2017 (suppl 6S; abstract 214)

DOI

10.1200/JCO.2017.35.6_suppl.214

Abstract #

214

Poster Bd #

H16

Abstract Disclosures

Similar Posters

First Author: Emily Nash Smyth

First Author: Shingo Hatakeyama

First Author: Celestia S. Higano

First Author: Guru Sonpavde